Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson's disease patients.
Authors
Zago, Elisa
Dal Molin, Alessandra
Dimitri, Giovanna Maria
Xumerle, Luciano
Pirazzini, Chiara
Bacalini, Maria Giulia
Maturo, Maria Giovanna
Azevedo, Tiago
Spasov, Simeon
Gómez-Garre, Pilar
Periñán, María Teresa
Jesús, Silvia
Baldelli, Luca
Sambati, Luisa
Calandra-Buonaura, Giovanna
Garagnani, Paolo
Provini, Federica
Cortelli, Pietro
Mir, Pablo
Trenkwalder, Claudia
Mollenhauer, Brit
Franceschi, Claudio
Liò, Pietro
Nardini, Christine
PROPAG-AGEING Consortium
Publication Date
2022-01-25Journal Title
Sci Rep
ISSN
2045-2322
Publisher
Springer Science and Business Media LLC
Volume
12
Issue
1
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Zago, E., Dal Molin, A., Dimitri, G. M., Xumerle, L., Pirazzini, C., Bacalini, M. G., Maturo, M. G., et al. (2022). Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson's disease patients.. Sci Rep, 12 (1) https://doi.org/10.1038/s41598-022-05227-6
Abstract
Advanced age represents one of the major risk factors for Parkinson's Disease. Recent biomedical studies posit a role for microRNAs, also known to be remodelled during ageing. However, the relationship between microRNA remodelling and ageing in Parkinson's Disease, has not been fully elucidated. Therefore, the aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson's Disease within the ageing framework. We employed Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson's Disease (recently diagnosed, drug-naïve) and healthy ageing (centenarians) plus healthy controls, age-matched with Parkinson's Disease patients. Potential microRNA candidates markers, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson's Disease patients, and healthy siblings of Parkinson's Disease patients at higher genetic risk for developing the disease. While we did not find evidences of microRNAs co-regulated in Parkinson's Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early Parkinson's Disease patients. Moreover, interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson's Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early Parkinson's Disease, robustly confirmed across a variety of analytical and experimental analyses. These promising results ask for further research to unveil the functional details of the involvement of hsa-mir144-3p in Parkinson's Disease.
Keywords
Article, /631/1647, /631/114, /631/250, /631/337, /692/308, /692/617, article
Sponsorship
European Commission Horizon 2020 (H2020) Industrial Leadership (IL) (634821)
Identifiers
s41598-022-05227-6, 5227
External DOI: https://doi.org/10.1038/s41598-022-05227-6
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333337
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk